MAIA Biotechnology Announces Efficacy Updates for THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According to the Form 8-K filed with the Securities and Exchange Commission, the efficacy updates were the main subject of the announcement.

Under Regulation FD, the press release concerning the trial updates has been provided as Exhibit 99.1 within the current report. It is important to note that the information contained in this report, along with the attached Exhibit 99.1, is considered “furnished” rather than “filed” under the Securities Exchange Act of 1934. Therefore, it does not hold the same legal weight as filed information.

Moreover, in a separate disclosure under Item 8.01, MAIA Biotechnology made a presentation regarding its business on February 5, 2025, which can be accessed on the company’s website. The presentation, available as Exhibit 99.2 in the report, is meant to provide insights into the company’s operations. Investors are advised to review this information along with the company’s regulatory filings and public announcements to gain a comprehensive understanding.

It is essential to interpret the presentation within the context of the company’s SEC filings and future public disclosures. While MAIA Biotechnology reserves the right to update the presentation to reflect any post-report events, they are not mandated to do so and have disclaimed any obligation in this regard.

As with forward-looking statements, investors are reminded to exercise caution and not overly rely on these projections. Forward-looking information is inherently subject to risks and uncertainties, and actual results may differ from what is predicted.

This Form 8-K also includes a list of exhibits, such as the press release dated February 4, 2025 (Exhibit 99.1), the presentation materials (Exhibit 99.2), and the Cover Page Interactive Data File. The filing has been duly signed by Vlad Vitoc, Chief Executive Officer of MAIA Biotechnology, Inc., in compliance with Securities Exchange Act requirements.

In summary, MAIA Biotechnology’s recent updates regarding its Phase 2 THIO-101 trial demonstrate the company’s commitment to communicating significant developments in its oncology research programs, highlighting its dedication to transparency and stakeholder engagement.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read MAIA Biotechnology’s 8K filing here.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.